Computational studies of new 1,4-dihydropyridines containing 4-(5)-chloro-2-ethyl-5-(4)-imidazolyl substituent: QSAR and docking

Medicinal Chemistry Research

Volumn 19, Issue 1, 2010, Pages 58-70

  Davood, Asghar ^a   Nematollahi, Alireza ^a   Iman, Maryam ^b   Shafiee, Abbas ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

1,4 Dihydropyridine; CCBs; Docking; Imidazole; Molecular modeling; QSAR

Indexed keywords

1,4 DIHYDROPYRIDINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE;

ANIMAL TISSUE; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG CONFORMATION; GUINEA PIG; IC 50; ILEUM; INTESTINE MUSCLE; MOLECULAR DOCKING; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 76449119392     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-009-9171-2     Document Type: Article

References (29)

1. MR Akula WC Matowe MW Woloyk EE Knaus 1989 Synthesis and calcium channel antagonist activity of alkyl cycloalkyl esters of nifedipine containing pyridinyl substituents Drug Deliv 5 117 123 1:STN:280:DyaK2czjtFWjtA%3D%3D
2. MR Akula WC Matowe MW Woloyk EE Knaus 1990 Synthesis and calcium channel antagonist activity of 3-arylmethyl 5-isopropyl 1,4-dihydro-2,6-dimethyl-4- (pyridyl)-3,5-pyridinedicarboxylates Pharm Res 7 919 922 10.1023/A:1015941706008 10.1023/A:1015941706008 1:CAS:528:DyaK3MXkt1Giug%3D%3D 2235890
3. BB Ana MA Rosa MJ Rosa W Wolfgang 2006 Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples Forensic Sci Int 156 23 34 10.1016/j.forsciint.2004.11.014 10.1016/j.forsciint. 2004.11.014 (Pubitemid 43061280)
4. JE Arrowsmith SF Campbell PE Cross JK Stubbs RA Burges 1986 Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents J Med Chem 29 1696 1702 10.1021/jm00159a022 10.1021/jm00159a022 1:CAS:528:DyaL28Xlslaht74%3D 2943898
5. Belleman P (1986) Innovative approaches in drug research. Elsevier, Amsterdam, pp 23-46
6. M Clark RD Cramer DM Jones DE Patterson PE Simeroth 1990 Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structuraldatabases Tetrahedron Comput Methodol 3 47 59 10.1016/0898-5529(90)90120-W 10.1016/0898-5529(90)90120-W 1:CAS:528:DyaK3MXhtVSmtbs%3D
7. RA Coburn MM Goodman KM Snader R Tedeschi E Macko 1988 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach J Med Chem 31 2103 2107 10.1021/jm00119a009 10.1021/jm00119a009 1:CAS:528:DyaL1cXls1aqs74%3D 2846838 (Pubitemid 18257973)
8. RD Cramer DE Patterson JD Bunce 1988 Comparative molecular fieldanalysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J Am Chem Soc 110 5959 5967 10.1021/ja00226a005 10.1021/ja00226a005 1:CAS:528: DyaL1cXltVCqsbs%3D (Pubitemid 18213690)
9. A Davood G Khodarahmi E Alipour A Dehpour M Amini A Shafiee 2001 Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4(5)-chloro-2-methyl-5(4)-imidazolyl substituent Boll Chim Farm 140 381 386 1:CAS:528:DC%2BD38XitFOiu7c%3D 11822226
10. A Davood N Mansouri A Dehpour H Shafaroudi E Alipour A Shafiee 2006 Design, synthesis, and calcium channel antagonist activity of new 1,4-dihydropyridines containing 4-(5)-chloro-2-ethyl-5-(4)-imidazolyl substituent Arch Pharm Chem Life Sci 339 299 304 10.1002/ardp.200600013 10.1002/ardp.200600013 1:CAS:528:DC%2BD28XmtFSksrY%3D (Pubitemid 43980044)
11. A Fleckenstein 1977 Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle Annu Rev Pharmacol Toxicol 17 149 166 10.1146/annurev.pa.17.040177.001053 10.1146/annurev.pa.17.040177.001053 1:CAS:528:DyaE2sXks1ahs78%3D 326161
12. AC Gaudio A Korolkovas Y Takahata 1994 Quantitative structure-activity relationships for 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues): a quantum/classical approach J Pharm Sci 83 1110 1115 10.1002/jps.2600830809 10.1002/jps.2600830809 1:CAS:528:DyaK2cXkslejtLg%3D 7983594 (Pubitemid 24247347)
13. S Goldmann J Stoltefuss 1991 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and calcium agonist activities Angew Chem Int Ed Engl 30 1559 1578 10.1002/anie.199115591 10.1002/anie.199115591
14. T Goodfraind R Miller M Wibo 1986 Calcium antagonism and calcium entry blockade Pharmacol Rev 38 321 416
15. P Gramatica E Papa 2003 QSAR Modeling of bioconcentration factor by theoretical molecular descriptors QSAR Comb Sci 22 374 385 10.1002/qsar. 200390027 10.1002/qsar.200390027 1:CAS:528:DC%2BD3sXkslOqtr4%3D
16. C Hansch 1969 A quantitative approach to biochemical structure-activity relation-ships Acc Chem Res 2 232 239 10.1021/ar50020a002 10.1021/ar50020a002 1:CAS:528:DyaF1MXkvVOnu74%3D
17. C Hansch T Fujita 1964 A method for the correlation of biological activity and chemical structure J Am Chem Soc 86 1616 1626 10.1021/ja01062a035 10.1021/ja01062a035 1:CAS:528:DyaF2cXptF2gsQ%3D%3D
18. Hansch C, Leo A (1995) Exploring QSAR. Fundamentals and applications in chemistry and biology. American Chemical Society, Washington, DC, p 551
19. C Hansch A Kurup R Garg H Gao 2001 Chem.-bioinformatics and QSAR A. review of QSAR lacking positive hydrophobic terms Chem Rev 101 619 672 10.1021/cr0000067 10.1021/cr0000067 1:CAS:528:DC%2BD3MXhtVCntbc%3D 11712499 (Pubitemid 35377680)
20. Huey R, Morris GM (2007) Using AutoDock 4 with AutoDockTools
21. RA Janis DJ Triggle 1983 New developments in Ca2+ channel antagonists J Med Chem 26 775 785 10.1021/jm00360a001 10.1021/jm00360a001 1:CAS:528: DyaL3sXhvFWjt78%3D 6304312
22. H Kubinyi 1997 QSAR and 3D QSAR in drug design. Part 1: Methodology Drug Discov Today 2 457 467 10.1016/S1359-6446(97)01079-9 10.1016/S1359-6446(97) 01079-9 1:CAS:528:DyaK2sXns1CqtL4%3D (Pubitemid 27450428)
23. H Kubinyi 1997 QSAR and 3D QSAR in drug design Part 2: Applications and problems Drug Discov Today 2 538 546 10.1016/S1359-6446(97)01084-2 10.1016/S1359-6446(97)01084-2 1:CAS:528:DyaK2sXotVKqtro%3D (Pubitemid 27512944)
24. E Ochoa M Suárez Y Verdecia B Pita N Martín M Quinteiro C Seoane JL Soto J Duque R Pomés 1998 Structural study of 3,4-dihydropyridones and furo[3,4-b]-2(1H)-pyridones as potential calcium channel modulators Tetrahedron 54 12409 12420 10.1016/S0040-4020(98)00760-1 10.1016/S0040-4020(98)00760-1 1:CAS:528:DyaK1cXmtlSlsb8%3D
25. F Pourmorad F Hadizadeh A Shafiee 1997 Synthesis and calcium channel activity of 4- imidazolyl- 1,4-dihydropyridines Pharm Sci 3 165 168 1:CAS:528:DyaK2sXlslens7o%3D
26. M Ramesh WC Matowe MW Wolowyk EE Knaus 1987 Synthesis and calcium channel antagonist activity of alkyl t-butyl esters of nifedipine analogues containing pyridinyl substituents Drug Deliv 2 79 89 1:STN:280:DyaL1MzltFemuw%3D%3D
27. G Rovnyak N Anderson J Gougoutas A Hederg SD Kimball M Malley S Moreland M Porubcan A Pudzianowski 1988 Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers J Med Chem 31 936 944 10.1021/jm00400a008 10.1021/jm00400a008 1:CAS:528:DyaL1cXhs1OhtLs%3D 2834556
28. A Shafiee AR Dehpour F Hadizadeh M Azimi 1987 Synthesis and calcium channel antagonist activity of nifedipine analogues with methylsulfonyl- imidazolyl substituent Pharm Acta Helv 73 75 79 10.1016/S0031-6865(98)00004-1 10.1016/S0031-6865(98)00004-1
29. A Shafiee R Miri AR Dehpour F Soleymani 1996 Synthesis and calcium-channel antagonist activity of nifedipine analogues containing nitroimidazolyl substituent Pharm Sci 2 541 543 1:CAS:528:DyaK2sXmtVKgtLw%3D